Capital Investment Advisors LLC Buys 1,919 Shares of Zoetis Inc. (NYSE:ZTS)

Capital Investment Advisors LLC boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 16.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,303 shares of the company's stock after acquiring an additional 1,919 shares during the quarter. Capital Investment Advisors LLC's holdings in Zoetis were worth $2,190,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mission Wealth Management LP lifted its stake in Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares during the period. VeraBank N.A. grew its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC increased its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its stake in shares of Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its position in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after acquiring an additional 65 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.9%

ZTS opened at $170.15 on Monday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm has a market capitalization of $75.75 billion, a PE ratio of 31.11, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company's 50-day moving average is $157.41 and its 200 day moving average is $164.21.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.38 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

Analyst Ratings Changes

ZTS has been the subject of a number of research reports. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.